ISOQOL 33rd Annual Conference

The increasing interest in the use of quality-of-life assessments and patient reported outcomes highlights that the messaging and supporting evidence is having an impact. At the 2026 conference we look to explore how the field should continue to evolve to maximize the reach and methodological quality of work being undertaken in the field. Across selected core areas of evaluation, education, and regulation we aim to showcase key drivers and considerations for enhancing the breadth and scope of PRO activity.

EvaluateSpeakers: Carla Dias Barbosa, MSc; Jan Štochl, PhD; Pat Johnson, MSThe 2025 conference will have provided an important platform for AI driven approaches in quality of life and PRO research. In this session, 2026, we aim to explore some of the classical/traditional approaches/ideas to measurement and analysis of PRO data that underpin the field.

EducateSpeakers: Lotte Haverman, PhD; Fleur Chandler, MSc; Tolulope Sajobi, PhDWhere do we go next to strengthen the focus and reach of education in patient reported outcomes in clinical practice and beyond? Covering a range of clinical contexts along with the patient/carer perspectives, this session will be designed to showcase examples of successful strategies and approaches to multi-stakeholder PRO education. Speakers may highlight novel methods to develop and deliver education and also consider how we might approach educating wider stakeholder groups (e.g. hospital/health care facility managers).

RegulateSpeakers: Ingunn Westerheim, MA; Lynda Doward, MRes; Robyn Bent, RN MSWith increasing emphasis on the value and importance of the patient’s voice in drug development, this session will present an overview of the most current guidance from international regulators and decision-makers. This will include historical development of methods and applications such as FDA PRO guidance’s (2005, 2009) to the development and publication of the Patient Focused Drug Development Methodological Series and include wider international guidance’s and perspectives from European and Asian regulators.